It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivones…
Market Samachar is a news aggregator. This article was originally published by FiercePharma. Tap the button above to read the full story on their site.